Induction and Characterization of Pulmonary Hypertension in Mice using the Hypoxia/SU5416 Model

被引:5
|
作者
Bikou, Olympia [1 ]
Hajjar, Roger J. [2 ]
Hadri, Lahouaria [1 ]
Sassi, Yassine [1 ]
机构
[1] Icahn Sch Med Mt Sinai, Cardiovasc Res Ctr, New York, NY 10029 USA
[2] Phospholamban Fdn, New York, NY USA
来源
基金
美国国家卫生研究院;
关键词
Medicine; Issue; 160; Hypoxia; SU5416; Sugen; pulmonary hypertension; PH; right ventricular pressure; pulmonary vascular remodeling; right ventricular remodeling; 5416/HYPOXIA MOUSE MODEL; ARTERIAL-HYPERTENSION; ANIMAL-MODELS;
D O I
10.3791/59252
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Pulmonary Hypertension (PH) is a pathophysiological condition, defined by a mean pulmonary arterial pressure exceeding 25 mm Hg at rest, as assessed by right heart catheterization. A broad spectrum of diseases can lead to PH, differing in their etiology, histopathology, clinical presentation, prognosis, and response to treatment. Despite significant progress in the last years, PH remains an uncured disease. Understanding the underlying mechanisms can pave the way for the development of new therapies. Animal models are important research tools to achieve this goal. Currently, there are several models available for recapitulating PH. This protocol describes a two-hit mouse PH model. The stimuli for PH development are hypoxia and the injection of SU5416, a vascular endothelial growth factor (VEGF) receptor antagonist. Three weeks after initiation of Hypoxia/SU5416, animals develop pulmonary vascular remodeling imitating the histopathological changes observed in human PH (predominantly Group 1). Vascular remodeling in the pulmonary circulation results in the remodeling of the right ventricle (RV). The procedures for measuring RV pressures (using the open chest method), the morphometrical analyses of the RV (by dissecting and weighing both cardiac ventricles) and the histological assessments of the remodeling (both pulmonary by assessing vascular remodeling and cardiac by assessing RV cardiomyocyte hypertrophy and fibrosis) are described in detail. The advantages of this protocol are the possibility of the application both in wild type and in genetically modified mice, the relatively easy and low-cost implementation, and the quick development of the disease of interest (3 weeks). Limitations of this method are that mice do not develop a severe phenotype and PH is reversible upon return to normoxia. Prevention, as well as therapy studies, can easily be implemented in this model, without the necessity of advanced skills (as opposed to surgical rodent models).
引用
收藏
页码:1 / 9
页数:9
相关论文
共 50 条
  • [1] Outcomes of pregnancy in mice with pulmonary hypertension induced by Hypoxia/SU5416
    Liu, Yang
    Deng, Jing
    Zhao, Yichen
    Liu, Kemin
    Zhang, Wenbo
    Wang, Qiang
    Wang, Jiangang
    Piao, Chunmei
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2023, 669 : 128 - 133
  • [2] Severe Emphysema in the SU5416/Hypoxia Rat Model of Pulmonary Hypertension
    Kojonazarov, Baktybek
    Hadzic, Stefan
    Ghofrani, Hossein Ardeschir
    Grimminger, Friedrich
    Seeger, Werner
    Weissmann, Norbert
    Schermuly, Ralph Theo
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 200 (04) : 515 - 518
  • [3] Pulmonary Emphysema in Rats with Severe Pulmonary Hypertension Induced by SU5416 and Hypoxia
    Kojonazarov, B.
    Hadzic, S.
    Ghofrani, H. A.
    Grimminger, F.
    Weissmann, N.
    Seeger, W.
    Schermuly, R. T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [4] Aquaporin 1 mediates microvascular endothelial dysfunction in the SU5416/hypoxia model of pulmonary hypertension
    Yun, Xin
    Philip, Nicolas M.
    Jiang, Haiyang
    Smith, Zion
    Huetsch, John
    Mahendra, Damarla
    Suresh, Karthik
    Shimoda, Larissa
    FASEB JOURNAL, 2022, 36
  • [5] Pneumonectomy combined with SU5416: A novel animal model of pulmonary hypertension
    Happe, Chris
    de Raaf, Michiel A.
    Schalij, Ingrid
    Vonk-Noordegraaf, Anton
    Westerhof, Nico
    de Man, Frances S.
    Bogaard, Harm-Jan
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [6] Gut microbiota modification suppresses the development of pulmonary arterial hypertension in an SU5416/hypoxia rat model
    Sanada, Takayuki J.
    Hosomi, Koji
    Shoji, Hiroki
    Park, Jonguk
    Naito, Akira
    Ikubo, Yumiko
    Yanagisawa, Asako
    Kobayashi, Takayuki
    Miwa, Hideki
    Suda, Rika
    Sakao, Seiichiro
    Mizuguchi, Kenji
    Kunisawa, Jun
    Tanabe, Nobuhiro
    Tatsumi, Koichiro
    PULMONARY CIRCULATION, 2020, 10 (03)
  • [7] Thioridazine Improves Pulmonary Arterial Pressure In The Su5416/chronic Hypoxia Rat Model Of Severe Pulmonary Arterial Hypertension
    Foster, W. S.
    Deng, Y.
    Taha, M.
    Stewart, D. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [8] A novel rat model of pulmonary hypertension induced by mono treatment with SU5416
    Yuqin Chen
    Meidan Kuang
    Shiyun Liu
    Chi Hou
    Xin Duan
    Kai Yang
    Wenjun He
    Jing Liao
    Qiuyu Zheng
    Guofa Zou
    Haixia Chen
    Han Yan
    Jiyuan Chen
    Yi Li
    Ying Zhou
    Xiaoyun Luo
    Qian Jiang
    Haiyang Tang
    Wenju Lu
    Jian Wang
    Hypertension Research, 2020, 43 : 754 - 764
  • [9] A novel rat model of pulmonary hypertension induced by mono treatment with SU5416
    Chen, Yuqin
    Kuang, Meidan
    Liu, Shiyun
    Hou, Chi
    Duan, Xin
    Yang, Kai
    He, Wenjun
    Liao, Jing
    Zheng, Qiuyu
    Zou, Guofa
    Chen, Haixia
    Yan, Han
    Chen, Jiyuan
    Li, Yi
    Zhou, Ying
    Luo, Xiaoyun
    Jiang, Qian
    Tang, Haiyang
    Lu, Wenju
    Wang, Jian
    HYPERTENSION RESEARCH, 2020, 43 (08) : 754 - 764
  • [10] The Effects of Antiangiogenic Compound SU5416 in a Rat Model of Pulmonary Arterial Hypertension
    Sakao, Seiichiro
    Tatsumi, Koichiro
    RESPIRATION, 2011, 81 (03) : 253 - 261